Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Ironwood Pharmaceuticals is a patient-focused, biotechnology company on a mission to advance the treatment of gastrointestinal (GI) diseases and redefine the standard of care for patients. At Ironwood, patients are at the center of everything we do. We’re committed to creating therapies that ease the burden of illness and meet important medical needs. We’re proud to have developed a first-in-class prescription medication, approved in the U.S. for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), as well as for children (ages 6 to 17) with functional constipation.
Through our STARS study program, we are also advancing research for people with short bowel syndrome (SBS) who rely on intravenous (IV) nutrition and/or hydration. Recognizing the complex and often isolating journey patients face, we have partnered with the SBS community and organizations such as IFFGD to create essential resources that help patients prepare for medical appointments and find support.
For more information, visit us at ironwoodpharma.com
